Oscilloquartz delivers assured timing for mission-critical harsh environments with ruggedSync ™ Series OSA 5510
1.6.2026 14:00:00 CEST | Business Wire | Press Release
Oscilloquartz today launched its ruggedSync™ Series OSA 5510, a ruggedized timing and synchronization platform engineered for defense and other harsh, mission-critical environments. Designed for deployment in tactical communications networks, mobile command centers (MCCs), aviation systems and other highly demanding operational environments, the OSA 5510 combines PTP grandmaster and NTP server functionality with synchronization assurance and resilient holdover in a compact MIL-qualified platform. Multi-band GNSS support, encrypted and authenticated timing options and environmental protection enable operation in contested and GNSS-denied environments where trusted synchronization must be maintained.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601763766/en/
Oscilloquartz’s ruggedSync™ Series OSA 5510 delivers resilient, high-precision timing for mission-critical defense networks.
“Our new ruggedSync™ Series OSA 5510 extends the Oscilloquartz assured PNT portfolio into tactical and deployable defense environments,” said Gil Biran, GM of Oscilloquartz. “Combined with our optical cesium clocks, synchronization assurance technologies, PTP grandmasters and synchronization management solutions, it reinforces Oscilloquartz’s ability to deliver the industry’s most comprehensive timing portfolio. This enables us to support truly end-to-end, multi-layered timing architectures designed to maintain trusted synchronization and resilient PNT capabilities across highly demanding and contested environments.”
Built to support resilient defense timing architectures, the OSA 5510 integrates advanced synchronization technologies and flexible mission-critical interfaces within a hardened platform compliant with MIL-STD-810H and MIL-STD-461G. The solution supports IEEE 1588v2 PTP, SyncE and secure NTP services, while programmable I/O and timecode interfaces, including STANAG, Have Quick, IRIG and PPS/CLK distribution, support diverse defense payloads and operational requirements. Optical and copper SFP/SFP+ 1G/10G interfaces and dual power feeds further enable deployment across modern high-bandwidth defense networks.
The ruggedSync™ Series OSA 5510 strengthens multi-source resilience through zero-trust architecture, with support for M-Code, Galileo PRS and Iridium STL. Extended holdover, low phase-noise outputs, and jamming and spoofing detection and mitigation help maintain continuity during GNSS degradation or disruption, while White Rabbit readiness supports advanced timing distribution use cases. The launch also builds on Oscilloquartz’s expanding global aerospace, defense and government partnerships, including regional representative and VAR relationships supporting resilient timing and assured PNT deployments across the Americas, EMEA and Asia-Pacific.
“Modern defense operations require synchronization technologies that are resilient, flexible and straightforward to integrate across diverse mission environments,” commented Igal Pinhasov, VP of product line management at Oscilloquartz. “Our OSA 5510 builds on the same core timing and synchronization technologies deployed across the broader Oscilloquartz portfolio, helping to deliver a more consistent operational experience across network layers and deployment models. By leveraging common capabilities and synchronization management approaches, organizations can simplify integration and more easily scale resilient timing infrastructures across evolving defense networks.”
About Oscilloquartz
Oscilloquartz, an Adtran company, delivers high-precision timing and synchronization solutions for mobile networks and critical infrastructure, enabling assured positioning, navigation and timing (aPNT) with multi-source resilience and long holdover. With over 75 years of expertise, Oscilloquartz combines innovation with proven reliability to strengthen network resilience in a GNSS-challenged world. Our portfolio includes optically pumped atomic cesium clocks, PTP grandmasters, GNSS receivers and advanced synchronization management tools for in-service assurance. These solutions maintain accuracy and availability even under jamming or spoofing attacks, supporting communications, power, aviation, transport, defense, finance and broadcast networks. For more information, please visit www.oscilloquartz.com.
Published by
Oscilloquartz
www.oscilloquartz.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260601763766/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Rob Fink
+1 646 809 4048
investor.relations@adtran.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom